Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on March 5, 2021. The registrant is a Delaware corporation with its principal executive offices in Cincinnati, Ohio, and its common stock trades on the Nasdaq Capital Market under the symbol ARPO. The company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the discontinuation of testing for the company's drug candidate, Razuprotafib, in the I-SPY COVID trial. On March 5, 2021, the Quantum Leap Healthcare Collaborative announced it was stopping the testing of this candidate within the trial.
Guidance, Outlook, and Risks
The filing incorporates a press release regarding the trial discontinuation but does not provide updated financial guidance, specific management commentary on future outlook, or a detailed risk assessment beyond the event itself. The discontinuation of the trial represents a significant development in the company's clinical pipeline.
Investor Verification Checklist
- Verify the impact of the I-SPY COVID trial discontinuation on the overall development timeline for Razuprotafib.
- Review the attached Exhibit 99.1 (Press Release) for specific reasons cited by the Quantum Leap Healthcare Collaborative for stopping the trial.
- Confirm the company's current cash runway and capital requirements given the setback in this specific clinical program.
- Check for any subsequent filings regarding the status of other clinical trials or pipeline assets.